Thank you to our speakers, sponsors, and delegates who joined us in Seoul for the summit! If you are interested in the 2027 event, please get in touch at info@hansonwade.com
Innovating Novel Payload, Dual Payload & Bispecific ADCs to Drive Platform Differentiation that Combats Resistance & Accelerates more ADCs to First & Best-in Class Drugs
The need to move away from biosimilars and innovate novel technologies, has taken the ADC field in South Korea by storm. With novel payloads, dual payloads, and bispecific ADCs taking the center stage, Korean developers are now focused on overcoming Topo 1 ADC challenges to first-in-class ADCs and maximizing success to improve their partnership opportunities with big pharma.
With this in mind, the 5th World ADC Summit South Korea (previously World ADC Asia) returned to provide you with the most comprehensive platform for South Korea’s rapidly growing ADC community.
Attendees joined the likes of Daiichi Sankyo, Astellas, Gilead, AbbVie, Kanaph Therapeutics, OBI Pharma, Aimed Bio, Huadong Medicine, and more, for end-to-end insights on the evolving ADC landscape, novel technologies, dual payloads, and bispecific ADCs to further their ADC development.
Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this was the opportunity to converge with peers working on targeted protein degradation (TPDs), Bispecifics, and T-cell engagers, who were aiming to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
-
Discovery and innovation coming out of Asia is booming, and this will be a great opportunity to exchange insights, build collaborations, and help translate that momentum into better outcomes for patients
Araris
-
I am excited to engage with global and local leaders in the rapidly evolving ADC landscape. South Korea is emerging as a key hub for ADC innovation, and I look forward to sharing our latest findings and discussing strategies to accelerate the development of ADC therapeutics with peers
Kanaph Therapeutics
-
I truly enjoyed the opportunity to connect with ADC-related experts and peers in such a scientifically rich and collaborative environment. What stood out most was the depth of the discussions on dual-payload ADCs and how openly everyone shared insights.
Immunwork
Download the 2026 Official Agenda to Explore:
- Your One-Stop Forum to Develop First- and Best-in-Class ADC Therapeutics
- Insights from 35+ Korean-Based and International Speakers
- Unrivalled Networking Opportunities with Professionals Working on ADCs, TPD & Induced Proximity, and Bispecifics & T-Cell Engagers
Official 2026 Partners
Senior Partners
Program Partners
Exhibition Partners
Attending Companies Included
Explore Related Events
Explore the 2026 Agenda
Hear the latest ADC technology innovations taking place within South Korea and gain exclusive insights on the progress in ADC development globally.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean ADC leaders.
Join Biopharma Experts
Be part of the hottest conversations with like-minded scientists, C-level executives, heads, managers, VPs, and more across discovery, clinical and CMC functions.